BCPC.NASDAQBalchem CORP
DEF: Balchem Corporation 2026 Annual Meeting Proxy Statement
Sentiment:
Proxy Statement
Balchem Corporation has issued its 2026 Proxy Statement, inviting shareholders to its virtual Annual Meeting on June 18, 2026, to vote on director elections, auditor ratification, and executive compensation.
Summary
- Balchem Corporation is holding its 2026 Annual Meeting of Shareholders virtually on June 18, 2026, at 8:30 a.m. EDT.
- Shareholders are asked to vote on the election of two Class 3 directors, the ratification of RSM US LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation (Say-on-Pay).
- The Board of Directors unanimously recommends voting FOR all director nominees, FOR the ratification of the auditor, and FOR the advisory approval of executive compensation.
- The company highlights its commitment to sound corporate governance, including independent directors, board committee oversight, and a robust enterprise risk management program.
- Balchem has adopted an Artificial Intelligence (AI) Use Policy and conducted cybersecurity tabletop exercises.
- The company's executive compensation philosophy emphasizes a pay-for-performance approach, linking a significant portion of compensation to corporate performance.
- Key 2025 financial highlights include $1.037 billion in net sales (an 8.8% increase) and Adjusted EBITDA of $274.9 million (a 9.8% increase).
- The company also reported adjusted net earnings of $167.9 million and adjusted diluted EPS of $5.15, representing increases of 17.4% and 17.8%, respectively.
- Balchem has a strong balance sheet with a net debt leverage ratio of 0.3x trailing twelve-month adjusted EBITDA.
- The annual dividend was increased by 10% to $0.96 per share, marking the seventeenth consecutive year of double-digit annual dividend increases.
- The filing details the company's business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
- Shareholders of record as of April 21, 2026, are entitled to vote.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive filing, primarily due to the strong financial performance reported for 2025, consistent dividend growth, and robust corporate governance practices highlighted.
Positives
- Net sales increased by 8.8% to $1.037 billion in 2025.
- Adjusted EBITDA increased by 9.8% to $274.9 million in 2025.
- Adjusted net earnings increased by 17.4% to $167.9 million in 2025.
- Adjusted diluted EPS increased by 17.8% to $5.15 in 2025.
- Operating cash flow was $216.6 million, and free cash flow was $173.6 million, with a free cash flow conversion of 103% of non-GAAP net earnings.
- Net debt leverage ratio remains strong at 0.3x trailing twelve-month adjusted EBITDA.
- The annual dividend was increased by 10% to $0.96 per share, continuing a streak of seventeen consecutive years of double-digit annual dividend increases.
- Growth was achieved across all three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
- Strong corporate governance practices are in place, with six of seven directors being independent.
- The company has adopted an AI Use Policy and conducted cybersecurity tabletop exercises.
- Shareholder support for executive compensation was high in the previous year (93.8%).
Negatives
- No specific negative financial results or operational setbacks are highlighted in the proxy statement.
- The filing is a proxy statement, which primarily focuses on governance and shareholder proposals rather than detailed financial performance that might reveal negatives.
Risks
- Forward-looking statements involve risks, uncertainties, and other factors beyond the company's control that could cause actual results to differ materially from expectations.
- Specific risks are detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings.
- Cybersecurity threats, despite extensive measures, could still have a material adverse effect on the company.
- The company's business is subject to general economic conditions and regulatory environments.
Future Outlook
The company's forward-looking statements, which are subject to risks and uncertainties, aim to convey expectations about future results, performance, or achievements. These statements are not guarantees, and actual results may differ materially due to various factors detailed in the company's SEC filings.
Management Comments
- "Balchem is committed to making the world a healthier place by delivering trusted, innovative, and science-based solutions for the health and nutritional needs of the world."
- "Our Board plays a pivotal role in overseeing the development and execution of our business strategy, risk management, and corporate governance."
- "Over the last year, we adopted an Artificial Intelligence (AI) Use Policy and AI governance structure, recognizing that AI tools can help increase employee productivity and innovation when used in a safe, ethical, and secure manner."
- "We hope you'll join us at our Annual Meeting of Shareholders on June 18. Thank you for your continued support and confidence in Balchem as we advance our vision of making the world a healthier place."
Industry Context
StockSavvy.ai notes that Balchem's focus on nutrition and health, animal nutrition, and specialty products aligns with growing global trends in health and wellness, sustainable agriculture, and specialized industrial applications. The company's consistent dividend growth and strong financial performance, as detailed in this proxy statement, suggest a stable and growing player within the specialty chemicals and ingredients sector.
Comparison to Industry Standards
- Balchem's peer group for compensation benchmarking includes companies like Ashland Global Corp., H.B. Fuller Co., Minerals Technologies, and Sensient Technologies, indicating its positioning within the specialty chemicals and ingredients industry.
- The company's dividend increase of 10% and seventeen consecutive years of double-digit increases surpass many industry standards for consistent shareholder returns.
- The company's cybersecurity practices align with the U.S. National Institute of Standards and Technology (NIST) framework, a widely recognized industry standard.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Six of the seven directors are independent under Nasdaq listing standards and the company's Corporate Governance Guidelines. All members of the Board's four committees are independent. | N/A | Enhances oversight and accountability, aligning with best practices. |
| Director Retirement Policy | Directors must retire at the conclusion of the term in which they reach the age of 70. | N/A | Ensures regular refreshment of the Board and brings in new perspectives. |
| Insider Trading Policy | Prohibits directors, officers, and employees from holding Balchem securities in a margin account or pledging them as collateral. | N/A | Reduces risk of insider misconduct and aligns interests with long-term shareholder value. |
| AI Use Policy | Adoption of an Artificial Intelligence (AI) Use Policy and AI governance structure. | 2025 | Addresses the responsible and ethical integration of AI technologies to enhance productivity and innovation. |
| Cybersecurity Training | Conducted cybersecurity tabletop exercises with the Board and senior management. | 2025 | Strengthens preparedness and response capabilities for cybersecurity threats. |
| Board Structure | The Board has seven directors, with six being independent. The company maintains a Lead Director role. | N/A | Provides a balanced leadership structure with independent oversight. |
| Committee Charters | Board committees (Audit, Compensation, Governance) have adopted charters reviewed annually. | N/A | Ensures clear definition and execution of committee responsibilities. |
| Stock Ownership Policy | Formal stock ownership requirements for directors and executive officers are in place. | N/A | Aligns management and director interests with those of shareholders. |
| Clawback Policy | Incentive-Based Compensation Recovery Policy allows for reimbursement of incentive compensation in case of financial restatement. | 2023 | Enhances accountability for financial reporting accuracy. |
Related Party Transactions
- The company has a related party transaction policy reviewed by the Audit Committee for transactions exceeding $120,000.
- Employment of executive officers and director compensation are pre-approved related party transactions.
- No related party transactions with a material interest were reported for 2025.
Stakeholder Impact
- Shareholders: The company's financial performance, dividend increases, and corporate governance practices are designed to enhance shareholder value.
- Employees: The adoption of an AI Use Policy and cybersecurity training aims to improve productivity and security. Executive compensation is tied to company performance.
- Customers: The company provides innovative solutions in nutrition and health, animal nutrition, and specialty products.
- Suppliers: The company has a Supplier Code of Conduct emphasizing commitment to human rights and safe work environments.
Next Steps
- Shareholders are encouraged to read the full proxy statement and vote their shares.
- The Annual Meeting will be held virtually on June 18, 2026.
- The Board will consider the results of the advisory Say-on-Pay vote in future compensation decisions.
- The company will continue to engage with shareholders on corporate governance, sustainability, and executive compensation matters.
- RSM US LLP will continue as the independent registered public accounting firm for fiscal year 2026, pending shareholder ratification.
Key Dates
| Date | Description |
|---|---|
| 1967-01-01T00:00:00.000Z | Founding year of Balchem Corporation. |
| 1970-01-01T00:00:00.000Z | Year Balchem became a publicly-traded company. |
| 2004-01-01T00:00:00.000Z | Year RSM began auditing Balchem's financial statements. |
| 2015-04-22T00:00:00.000Z | Date of the employment agreement with Mr. Harris. |
| 2017-01-01T00:00:00.000Z | Mr. Harris became Chairman of the Board. |
| 2017-02-21T00:00:00.000Z | Grant date for some outstanding stock options. |
| 2018-01-01T00:00:00.000Z | Mr. Knutson became Chair of the Audit Committee. |
| 2019-01-01T00:00:00.000Z | Grant date for some outstanding stock options. |
| 2020-12-31T00:00:00.000Z | Baseline year for ESG goals (reducing greenhouse gas emissions and water withdrawal). |
| 2021-12-31T00:00:00.000Z | End of fiscal year for Pay Versus Performance disclosure. |
| 2022-01-01T00:00:00.000Z | Start of fiscal year for Pay Versus Performance disclosure and ESG modifier in ICP. |
| 2022-01-01T00:00:00.000Z | Grant date for some outstanding stock options. |
| 2022-10-31T00:00:00.000Z | Grant date for some Time-based Restricted Shares. |
| 2023-01-01T00:00:00.000Z | Start of fiscal year for Pay Versus Performance disclosure. |
| 2023-02-08T00:00:00.000Z | Grant date for some outstanding stock options and restricted shares. |
| 2023-02-12T00:00:00.000Z | Adoption of the Balchem Corporation Executive Severance Policy. |
| 2023-02-13T00:00:00.000Z | Date of Compensation Committee determination that performance targets for the 2023-2025 performance period had been met. |
| 2023-03-01T00:00:00.000Z | Ms. Fish served as Chair of the Governance Committee since this date. |
| 2023-06-18T00:00:00.000Z | Mr. Wineinger served as Lead Director and Chair of Compensation and Executive Committees since this date. |
| 2023-12-01T00:00:00.000Z | Peer group was refreshed for benchmarking purposes. |
| 2024-01-01T00:00:00.000Z | Start of fiscal year for Pay Versus Performance disclosure. |
| 2024-02-10T00:00:00.000Z | Late filing of Form 4 for William Backus. |
| 2024-02-13T00:00:00.000Z | Vanguard Group filed Schedule 13G/A. |
| 2024-05-14T00:00:00.000Z | APG Asset Management US Inc. filed Schedule 13G/A. |
| 2025-01-01T00:00:00.000Z | Start of fiscal year for Pay Versus Performance disclosure. |
| 2025-02-11T00:00:00.000Z | Compensation Committee reviewed 2025 financial results and approved ICP payout. |
| 2025-02-12T00:00:00.000Z | Each Non-Executive Director was granted 980 Time-Based Restricted Shares. |
| 2025-02-12T00:00:00.000Z | Compensation Committee approved the adoption of the Balchem Corporation Executive Severance Policy. |
| 2025-02-13T00:00:00.000Z | Compensation Committee reviewed 2023-2025 Performance Share grant payout. |
| 2025-02-20T00:00:00.000Z | Annual Report on Form 10-K for the year ended December 31, 2025, was filed with the SEC. |
| 2025-03-31T00:00:00.000Z | APG Asset Management US Inc. reported beneficial ownership as of this date. |
| 2025-04-01T00:00:00.000Z | Vesting of certain restricted shares occurred. |
| 2025-04-22T00:00:00.000Z | Mr. Harris's employment agreement entered into. |
| 2025-06-18T00:00:00.000Z | Ms. Vicente was appointed to the Governance Committee and Mr. Wineinger to the Audit Committee. |
| 2025-12-31T00:00:00.000Z | Record date for determining shareholders entitled to vote at the 2026 Annual Meeting. |
| 2026-01-01T00:00:00.000Z | Start of fiscal year for Pay Versus Performance disclosure. |
| 2026-01-01T00:00:00.000Z | Mr. Harris has been the Chair since this date. |
| 2026-02-10T00:00:00.000Z | Form 4 filing for William Backus made late. |
| 2026-02-11T00:00:00.000Z | Compensation Committee reviewed 2025 financial results and approved ICP payout. |
| 2026-02-12T00:00:00.000Z | Each Non-Executive Director was granted 980 Time-Based Restricted Shares. |
| 2026-02-13T00:00:00.000Z | Compensation Committee reviewed 2023-2025 Performance Share grant payout. |
| 2026-02-20T00:00:00.000Z | Annual Report on Form 10-K for the year ended December 31, 2025, was filed with the SEC. |
| 2026-03-22T00:00:00.000Z | Deadline for shareholders to submit advance written notice of nominations or other business for the 2027 Annual Meeting. |
| 2026-04-21T00:00:00.000Z | Record date for determining shareholders entitled to vote at the 2026 Annual Meeting. |
| 2026-04-27T00:00:00.000Z | Proxy Statement and Notice of Annual Meeting are first made available or mailed to shareholders. |
| 2026-06-17T23:59:00.000Z | Deadline to change vote or revoke proxy via Internet, telephone, or mail. |
| 2026-06-18T08:15:00.000Z | Virtual Annual Meeting platform opens for login. |
| 2026-06-18T08:30:00.000Z | 2026 Annual Meeting of Shareholders begins. |
| 2026-08-17T00:00:00.000Z | Latest date for timely shareholder notice for the 2027 Annual Meeting if announced after May 19, 2027. |
| 2027-12-28T00:00:00.000Z | Deadline for shareholders to submit proposals for inclusion in the 2027 Proxy Statement. |
Recommendation
holdThis filing is a proxy statement for an annual meeting, not a report on recent financial performance or strategic events that would typically drive a buy/sell recommendation. While the company reports positive financial results for 2025 and strong governance, the information is forward-looking and related to shareholder voting matters. A seasoned investor would await more specific operational or financial updates before making a definitive recommendation.
Keywords
Balchem Corporation, Proxy Statement, Annual Meeting, Shareholder Meeting, Director Election, Independent Auditor, Executive Compensation, Corporate Governance, RSM US LLP, BCPC, Virtual Meeting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.